Andrew McDonald

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy

Nicolás Novitzky, J. G. Thomson, Louise Abrahams et al. · British Journal of Haematology · 2005 · 73 citations · Full text

Medicine, Hematology, Immunology +9

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

Xiangping Qian, Andrew McDonald, Han-Jie Zhou et al. · ACS Medicinal Chemistry Letters · 2010 · 64 citations

Pharmacy, Medicinal Chemistry, Pharmacology +7